Tweet by Alberto J Espay on infographic. Donanemab in AD Posted byJoseph Thornton MDJuly 18, 2023Posted inBlog Alberto J Espay @AlbertoEspay Donanemab in early symptomatic Alzheimer’s disease – Infographic of the phase 3 trial data published by JAMA earlier today. Highlights: • No improvement • ~3-point less worsening in iADRS (below MCID) • 3.4% slower decline (not 35%!) @alzforum @alzassociation pic.twitter.com/5vbEt6NEOv 7/17/23, 3:59 PM Joseph Thornton Share this: Share on X (Opens in new window) X Share on Facebook (Opens in new window) Facebook Like Loading... Related Published by Joseph Thornton MD Teacher, Clinical Supervisor Clinical Associate Professor, Psychiatry University of Florida Affiliation is for identification only. All content and opinions are my own. View more posts
Gator Psychiatry 